Sebia launches M-inSight, a test for monitoring multiple myeloma patients

Sebia announced the launch of its serum based Minimal Residual Disease (MRD) test for monitoring in multiple myeloma. M-inSight is a Laboratory Developed Test (LDT) being offered by Corgenix, College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA) – licensed clinical laboratory and part of the Sebia Group. 

M-inSight is a personalized, targeted mass spectrometry assay, to detect with sensitivity the monoclonal protein (M-protein) secreted by the patient’s tumor cells in serum. The technology is based on clonotypic peptides mass spectrometry, which avoids the interference with the polyclonal background leading to an ultra-sensitive test. 

Read the full release here